Source: Investigational New Drugs. Unidades: ICB, IQSC
Subjects: FARMACOLOGIA, LEUCEMIA, ANTINEOPLÁSICOS, FOSFOPROTEÍNAS, MICROTÚBULOS, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, CITOESQUELETO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs, v. 39, n. 4, p. 1139-1149, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01066-w. Acesso em: 01 nov. 2024.APA
Carlos, J. A. E. G., Lima, K., Costa-Lotufo, L. V., Leitão, A., & Machado Neto, J. A. (2021). AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs, 39( 4), 1139-1149. doi:10.1007/s10637-021-01066-wNLM
Carlos JAEG, Lima K, Costa-Lotufo LV, Leitão A, Machado Neto JA. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis [Internet]. Investigational New Drugs. 2021 ; 39( 4): 1139-1149.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s10637-021-01066-wVancouver
Carlos JAEG, Lima K, Costa-Lotufo LV, Leitão A, Machado Neto JA. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis [Internet]. Investigational New Drugs. 2021 ; 39( 4): 1139-1149.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s10637-021-01066-w